# US 2014/0154235 A1 · Wound debridement compositions containing seaprose and methods of wound treatment using same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0154235 A1 - Document ID: US20140154235A1 - Status: Published application - Kind: A1 - Application number: 14/116,728 - Filed: 2012-05-11 - Published: 2014-06-05 - Earliest claimed: 2011-05-12 - Assignees: Smith & Nephew Orthopaedics AG - Inventors: Lei Shi; Aleksa Jovanovic; Dennis Carson - Web page: https://patentgrep.com/patent/US20140154235A1 ## CPC - A61K 38/482: {Serine endopeptidases (3.4.21)} - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} - A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite - A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers - A61K 47/38: Cellulose; Derivatives thereof - A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14) - A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C12Y 304/21063: Oryzin (3.4.21.63) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12Y: ENZYMES ## Abstract Wound debridement compositions containing the proteolytic enzyme Seaprose and use of such compositions in wound treatment for the enzymatic debridement of wounds. ## Claims ### Claim 1 A method of debriding a wound that includes necrotic tissue comprising applying to the wound a composition comprising Seaprose, wherein application of the composition debrides necrotic tissue in the wound. ### Claim 2 (depends on 1) The method of claim 1, wherein the necrotic tissue is an eschar. ### Claim 3 (depends on 1) The method of claim 1, wherein the composition is topically applied to the wound. ### Claim 4 (depends on 1) The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable topical carrier. ### Claim 5 (depends on 1) The method of claim 1, wherein the wound is a chronic wound. ### Claim 6 (depends on 5) The method of claim 5, wherein the chronic wound is a diabetic foot ulcer, a venous leg ulcer, an arterial leg ulcer, a decubitus ulcer, a stasis ulcer, a dermal ulcer, a burn, or a pressure ulcer. ### Claim 7 (depends on 1) The method of claim 1, wherein the composition includes 0.1 to 2% by weight of Seaprose. ### Claim 8 (depends on 7) The method of claim 7, wherein the composition includes 0.5 to 1% by weight of Seaprose. ### Claim 9 (depends on 1) The method of claim 1, wherein the Seaprose is isolated or purified Seaprose. ### Claim 10 (depends on 1) The method of claim 1, wherein the composition is formulated as a gel, cream, or ointment. ### Claim 11 (depends on 1) The method of claim 1, wherein the composition further comprises glycerin polyacrylate clatharate, glycerin, hydroxyethylcellulose, an emulsifying wax, or petrolatum, or any combination thereof. ### Claim 12 (depends on 1) The method of claim 1, wherein the composition is injected into the wound. ### Claim 13 (depends on 12) The method of claim 12, wherein the composition further comprises a pharmaceutically acceptable injectible carrier. ### Claim at position 14 14-24. (canceled) ### Claim 25 A topical composition for the debridement of wounds comprising a wound debridement effective amount of Seaprose and a pharmaceutically acceptable topical carrier. ### Claim 26 (depends on 25) The topical composition of claim 25, wherein the composition includes 0.1 to 2% by weight of Seaprose. ### Claim 27 (depends on 26) The topical composition of claim 26, wherein the composition includes 0.5 to 1% by weight of Seaprose. ### Claim 28 (depends on 25) The topical composition of claim 25, wherein the Seaprose is isolated or purified Seaprose. ### Claim 29 (depends on 25) The topical composition of claim 25, wherein the composition is formulated as a gel, cream, or ointment. ### Claim 30 (depends on 25) The topical composition of claim 25, wherein the composition is an ointment comprising petrolatum. ### Claim 31 (depends on 25) The topical composition of claim 25, wherein the composition is a gel comprising glycerin polyacrylate clatharate. ### Claim 32 (depends on 25) The topical composition of claim 25, wherein the composition is a gel comprising hydroxyethylcellulose. ### Claim 33 (depends on 25) The topical composition of claim 25, wherein the composition is a cream comprising glycerin and an emulsifying wax.